A detailed history of Ken Fisher (Fisher Asset Management, LLC) transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Fisher Asset Management, LLC holds 18,155 shares of SRPT stock, worth $2.16 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,155
Previous 17,916 1.33%
Holding current value
$2.16 Million
Previous $2.83 Million 19.89%
% of portfolio
0.0%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$124.33 - $156.75 $29,714 - $37,463
239 Added 1.33%
18,155 $2.27 Million
Q2 2024

Aug 14, 2024

SELL
$113.33 - $163.85 $11,899 - $17,204
-105 Reduced 0.58%
17,916 $2.83 Million
Q1 2024

May 09, 2024

BUY
$93.7 - $141.53 $412,654 - $623,298
4,404 Added 32.34%
18,021 $2.33 Million
Q3 2023

Nov 13, 2023

SELL
$102.5 - $123.59 $369,307 - $445,294
-3,603 Reduced 20.92%
13,617 $1.65 Million
Q2 2023

Dec 12, 2023

BUY
$106.4 - $157.19 $383,359 - $566,355
3,603 Added 26.46%
17,220 $1.97 Million
Q2 2023

Aug 08, 2023

BUY
$106.4 - $157.19 $501,888 - $741,465
4,717 Added 37.73%
17,220 $1.97 Million
Q1 2023

Dec 12, 2023

BUY
$117.53 - $155.99 $76,159 - $101,081
648 Added 4.76%
14,265 $1.97 Million
Q1 2023

May 01, 2023

SELL
$117.53 - $155.99 $2,820 - $3,743
-24 Reduced 0.19%
12,503 $1.72 Million
Q4 2022

Feb 03, 2023

SELL
$100.86 - $132.13 $1.24 Million - $1.63 Million
-12,317 Reduced 49.58%
12,527 $1.62 Million
Q3 2022

Nov 08, 2022

SELL
$75.71 - $119.24 $299,963 - $472,428
-3,962 Reduced 13.75%
24,844 $2.75 Million
Q2 2022

Aug 09, 2022

SELL
$62.69 - $88.44 $169,012 - $238,434
-2,696 Reduced 8.56%
28,806 $2.16 Million
Q1 2022

May 05, 2022

SELL
$63.15 - $90.42 $4,925 - $7,052
-78 Reduced 0.25%
31,502 $2.46 Million
Q4 2021

Feb 02, 2022

BUY
$77.28 - $99.42 $10,664 - $13,719
138 Added 0.44%
31,580 $2.84 Million
Q3 2021

Oct 26, 2021

BUY
$65.97 - $92.48 $229,179 - $321,275
3,474 Added 12.42%
31,442 $2.91 Million
Q2 2021

Jul 27, 2021

SELL
$69.38 - $86.75 $34,828 - $43,548
-502 Reduced 1.76%
27,968 $2.17 Million
Q1 2021

Apr 27, 2021

BUY
$72.25 - $168.95 $19,290 - $45,109
267 Added 0.95%
28,470 $2.12 Million
Q4 2020

Jan 29, 2021

SELL
$125.56 - $178.74 $523,961 - $745,882
-4,173 Reduced 12.89%
28,203 $4.81 Million
Q3 2020

Nov 10, 2020

SELL
$127.12 - $172.34 $496,657 - $673,332
-3,907 Reduced 10.77%
32,376 $4.55 Million
Q2 2020

Aug 07, 2020

SELL
$93.0 - $171.7 $425,568 - $785,699
-4,576 Reduced 11.2%
36,283 $5.82 Million
Q1 2020

Apr 28, 2020

BUY
$82.38 - $131.64 $546,426 - $873,168
6,633 Added 19.38%
40,859 $4 Million
Q4 2019

Feb 12, 2020

SELL
$76.53 - $135.58 $146,554 - $259,635
-1,915 Reduced 5.3%
34,226 $4.42 Million
Q3 2019

Oct 29, 2019

BUY
$72.81 - $156.91 $50,457 - $108,738
693 Added 1.95%
36,141 $2.72 Million
Q2 2019

Jul 30, 2019

BUY
$112.21 - $151.95 $1.21 Million - $1.64 Million
10,788 Added 43.75%
35,448 $5.39 Million
Q1 2019

Apr 22, 2019

BUY
$106.67 - $151.68 $6,613 - $9,404
62 Added 0.25%
24,660 $2.94 Million
Q4 2018

Jan 25, 2019

BUY
$97.32 - $148.76 $12,943 - $19,785
133 Added 0.54%
24,598 $2.68 Million
Q3 2018

Oct 24, 2018

SELL
$115.31 - $161.51 $1.01 Million - $1.41 Million
-8,722 Reduced 26.28%
24,465 $3.95 Million
Q2 2018

Jul 09, 2018

SELL
$71.74 - $153.69 $433,596 - $928,902
-6,044 Reduced 15.41%
33,187 $4.39 Million
Q1 2018

May 11, 2018

SELL
$54.02 - $82.27 $983,164 - $1.5 Million
-18,200 Reduced 31.69%
39,231 $2.91 Million
Q1 2018

Apr 19, 2018

BUY
$54.02 - $82.27 $798,577 - $1.22 Million
14,783 Added 34.66%
57,431 $4.26 Million
Q4 2017

Jan 24, 2018

BUY
$47.64 - $56.75 $285 - $340
6 Added 0.01%
42,648 $2.37 Million
Q3 2017

Oct 17, 2017

BUY
$35.73 - $47.15 $1.52 Million - $2.01 Million
42,642
42,642 $1.93 Million

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $10.4B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track Ken Fisher's Portfolio

Track Ken Fisher Portfolio

Follow Ken Fisher (Fisher Asset Management, LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fisher Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fisher Asset Management, LLC and Ken Fisher with notifications on news.